Effects of traditional Chinese medicine on treatment outcomes in severe COVID-19 patients: a single-centre study

Abstract

As the search for effective treatments for COVID-19 continues, the high mortality rate among critically ill patients in Intensive Care Units (ICU) presents a profound challenge. This study explores the potential benefits of traditional Chinese medicine (TCM) as a supplementary treatment for severe COVID-19. A total of 110 critically ill COVID-19 patients at the Intensive Care Unit (ICU) of Vulcan Hill Hospital between Feb., 2020, and April, 2020 (Wuhan, China) participated in this observational study. All patients received standard supportive care protocols, with a subset of 81 also receiving TCM as an adjunct treatment. Clinical characteristics during the treatment period and the clinical outcome of each patient were closely monitored and analysed. Our findings indicated that the TCM group exhibited a significantly lower mortality rate compared with the non-TCM group (16 of 81 vs 24 of 29; 0.3 vs 2.3 person/month). In the adjusted Cox proportional hazards models, TCM treatment was associated with improved survival odds (P < 0.001). Furthermore, the analysis also revealed that TCM treatment could partially mitigate inflammatory responses, as evidenced by the reduced levels of proinflammatory cytokines, and contribute to the recovery of multiple organic functions, thereby potentially increasing the survival rate of critically ill COVID-19 patients.

Keywords

COVID-19 / Pneumonia / Novel coronavirus / Critically ill / Traditional Chinese medicine / Clinical outcome

References

[1] Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review[J]. JAMA, 2020, 324(8): 782-793.

[2] Shiehzadegan S, Alaghemand N, Fox M, et al. Analysis of the Delta variant B.1.617.2 COVID-19[J]. Clin Pract, 2021, 11(4): 778-784.

[3] Manjunath R, Gaonkar SL, Saleh EAM, et al. A comprehensive review on COVID-19 Omicron (B.1.1.529) variant[J]. Saudi J Biol Sci, 2022, 29(9): 103372.

[4] Tian D, Sun Y, Xu H, et al. The emergence and epidemic characteristics of the highly mutated SARS-CoV-2 Omicron variant[J]. J Med Virol, 2022, 94(6): 2376-2383.

[5] Le TTB, Vasanthakumaran T, Thi HHN, et al. SARS-CoV-2 Omicron and its current known unknowns: a narrative review[J]. Rev Med Virol, 2023, 33(1): e2398.

[6] Alhazzani W, Moller MH, Arabi YM, et al. Surviving sepsis campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)[J]. Crit Care Med, 2020, 48(6): e440-e469.

[7] Wilson KC, Chotirmall SH, Bai C, et al. COVID-19: interim guidance on management pending empirical evidence[J]. NEJM, 2020, 2020: 12.

[8] National Institutes of Health (US).Coronavirus Disease 2019 (COVID-19) Treatment Guidelines [S]. Bethesda (MD), 2021.

[9] Zheng Y, Jin D, Lin J, et al. Understanding COVID-19 in Wuhan from the perspective of cold-dampness: clinical evidences and mechanisms[J]. Front Med (Lausanne), 2021, 8: 617659.

[10] Chen YY, Zhang C, Wang N, et al. Deciphering suppressive effects of Lianhua Qingwen Capsule on COVID-19 and synergistic effects of its major botanical drug pairs[J]. Chin J Nat Med, 2023, 21(5): 383-400.

[11] Wei WL, Wu SF, Li HJ, et al. Chemical profiling of Huashi Baidu Prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS[J]. Chin J Nat Med, 2021, 19(6): 473-480.

[12] Zhou S, Feng J, Xie Q, et al. Traditional Chinese medicine Shenhuang Granule in patients with severe/critical COVID-19: a randomized controlled multicenter trial[J]. Phytomedicine, 2021, 89: 153612.

[13] Ye YA, Group GCC. Guideline-based Chinese herbal medicine treatment plus standard care for severe coronavirus disease 2019 (G-CHAMPS): evidence from China[J]. Front Med (Lausanne), 2020, 7: 256.

[14] Yan BH, Jiang ZW, Zeng JP, et al. Large-scale prospective clinical study on prophylactic intervention of COVID-19 in community population using Huoxiang Zhengqi Oral Liquid and Jinhao Jiere Granules[J]. Chin J Chin Mater Med, 2020, 45(13): 2993-3000.

[15] Xiao M, Tian J, Zhou Y, et al. Efficacy of Huoxiang Zhengqi Dropping Pills and Lianhua Qingwen Granules in treatment of COVID-19: a randomized controlled trial[J]. Pharmacol Res, 2020, 161: 105126.

[16] Wu J, Tang F, Zhang XQ, et al. Application of Jiawei Maxing Shigan Tang in the treatment of COVID-19: an observational study[J]. Front Med (Lausanne), 2022, 9: 1028171.

[17] Marini JJ, Gattinoni LJJ. Management of COVID-19 respiratory distress[J]. JAMA, 2020, 323(22): 2329-2330.

[18] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506.

[19] Zanza C, Romenskaya T, Manetti AC, et al. Cytokine storm in COVID-19: immunopathogenesis and therapy[J]. Medicina (Kaunas), 2022, 58(2): 144.

[20] Horby P, Lim WS, Emberson J, et al. Effect of dexamethasone in hospitalized patients with COVID-19, preliminary report[J]. MedRxiv, 2020, 2020: 2020.06.22.20137273.

[21] Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review[J]. JAMA, 2020, 323(18): 1824-1836.

[22] McMahon JH, Udy A, Peleg AY. Remdesivir for the treatment of COVID-19-preliminary report[J]. N Engl J Med, 2020, 383(10): 992-993.

[23] Ge H, Wang YF, Xu J, et al. Anti-influenza agents from traditional Chinese medicine[J]. Nat Prod Rep, 2010, 27(12): 1758-1780.

[24] Duan ZP, Jia ZH, Zhang J, et al. Natural herbal medicine Lianhuaqingwen Capsule anti-influenza A (H1N1) trial: a randomized, double blind, positive controlled clinical trial[J]. Chin Med J (Engl), 2011, 124(18): 2925-2933.

[25] Li LC, Zhang ZH, Zhou WC, et al. Lianhua Qingwen Prescription for coronavirus disease 2019 (COVID-19) treatment: advances and prospects[J]. Biomed Pharmacother, 2020, 130: 110641.

[26] Qiao Y, Xu X, Zhou F, et al. Effect of Lianhua Qingwen Capsules on the positive rate of COVID-19 close contacts: a retrospective analysis of a large-scale population-based cohort study[J]. Phytomedicine, 2023, 112: 154690.

[27] Hu K, Guan WJ, Bi Y, et al. Efficacy and safety of Lianhuaqingwen Capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: a multicenter, prospective, randomized controlled trial[J]. Phytomedicine, 2021, 85: 153242.

[28] Li YX, Li RH. Anti-inflammatory activity of volatile oil extracted from Atractylodes lancea[J]. J Liaoning Univ Tradit Chin Med, 2013, 15(2): 71-72.

[29] Huang X, Xiu H, Zhang S, et al. The role of mmacrophages in the pathogenesis of ALI/ARDS[J]. Mediators Inflamm, 2018, 2018: 1264913.

[30] Huang CQ, Li W, Wu B, et al. Pheretima aspergillum decoction suppresses inflammation and relieves asthma in a mouse model of bronchial asthma by NF-kappaB inhibition[J]. J Ethnopharmacol, 2016, 189: 22-30.

[31] Li RF, Hou YL, Huang JC, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)[J]. Pharmacol Res, 2020, 156: 104761.

[32] Li JH, Wang RQ, Guo WJ, et al. Efficacy and safety of traditional Chinese medicine for the treatment of influenza A (H1N1): a meta-analysis[J]. J Chin Med Assoc, 2016, 79(5): 281-291.

[33] Dong L, Xia JW, Gong Y, et al. Effect of lianhuaqingwen capsules on airway inflammation in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Evid-Based Compl Alt, 2014, 2014: 637969.

Funding

National Science Foundation for Young Scientists of China(82100096)

National Science Foundation for Young Scientists of Beijing(7214254)

National Natural Science Foundation of China(81902426)

National Natural Science Foundation of China(81872441)

Emergency Scientific Research Project for COVID-19(20yjky007)